Ernst Berndt

Louis E. Seley Professor in Applied Economics
Professor of Applied Economics

Biography | Selected Publications

“The Hidden Cost of Low Prices: Limited Access to New Drugs in India,”  Berndt, Ernst R. and Iain M. Cockburn. Health Affairs, 33(9):1567-75, September 2014.

"Price Indexes for Clinical Trial Research: A Feasibility Study,” Berndt, Ernst R. and Iain M. Cockburn. Monthly Labor Review, June 2014, 20 pp.

“Concentration and Changes in Physician Prescribing of Antipsychotic Medications”, Donohue, Julie M., A. James O’Malley, Marcela Horvitz-Lennon, Anna Levine Taub, Ernst R. Berndt and Haiden Huskamp. Psychiatric Services, 2014 March 1; 65(3):315-322.  doi: 10.1176/appi.ps.201200536.

(2014)

"Vaccine Economics”, McElligott, Sean, and Ernst R. Berndt in Anthony Culyer, ed., Encyclopedia of Health Economics, First Edition, San Diego, CA: Elsevier Inc., 2014, 425-431.

“Defining and Quantifying the Use of Personalized Medicines”, Hu, Sean X., Murray L. Aitken, Arnold M. Epstein, Mark R. Trusheim and Ernst R. Berndt. Nature Reviews:  Drug Discovery, online version published 29 November 2013, http://www.nature.com/nrd/journal/v12/n12/full/nrd4177.html?WT.ec_id=NRD-201312. Hard copy version published December 2013.

“Comparison of Stakeholder Metrics for Traditional and Adaptive Development and Licensing Approaches to Drug Development,” Baird, Lynn G., Mark R. Trusheim, Hans-Georg Eichler, Ernst R. Berndt and Gigi M. Hirsch. Therapeutic Innovation & Regulatory Science, 47(4):474-483, July 2013

“The Impact of Emerging Safety and Effectiveness Evidence on the Use of Physician-administered Drugs: The Case of Bevacizumab for Breast Cancer”, Conti, Rena M., Stacie B. Dusetzina, Ann C. Herbert, Ernst R. Berndt, Haiden A. Huskamp and Nancy L. Keating. Medical Care 51(7):622-627, July 2013

“Defining and Quantifying the Use of Personalized Medicines” with Sean X. Hu, Murray L. Aitken, Arnold M. Epstein, and Mark R. Trusheim, Nature Reviews: Drug Discovery, online version published 29 November 2013, http://www.nature.com/nrd/journal/v12/n12/full/nrd4177.html?WT.ec_id=NRD-201312. Hard copy version to be published December 2013.

“How Quickly Do Physicians Adopt New Drugs? The Case of Antipsychotics” with Haiden A. Huskamp, Alistar J. O'Malley, Marcela Horvitz-Lennon, Anna Levine Taub and Julie M. Donohue, Psychiatric Services, 64(4):324-330, April 2013.

“Promotion of Prescription Drugs to Consumers and Providers, 2001-2010” with Rachel Kornfield, Julie Donohue and G. Caleb Alexander, PLOS ONE, 8(3):e55504. Doi:10.1371/journal.pone.0055504, published March 4, 2013.

“Uncertain prognosis for high-quality diagnostics: clinical challenges, economic barriers and needed reforms” with Mark R. Trusheim, M.J. Finley Austin and Carsten Rausch, Pharmacogenomics, (2013) 14(3):325-334. (2013)

“Winners and Losers From the Zaltrap Price Discount: Unintended Consequences?” with Rena Conti, Health Affairs Blog, available at http://healthaffairs.org/blog/2013/02/20/winners-and-losers-from-the-zaltrap-price-discount, posted February 20, 2013

“Economic Challenges and Possible Policy Actions to Advance Stratified Medicine” with Mark R. Trusheim, Personalized Medicine, 9(4):413-27, 2012.

“Economic Challenges and Possible Policy Actions to Advance Stratified Medicine” with Mark R. Trusheim, Personalized Medicine, 9(4):413-27, 2012.

“Pricing and Reimbursement in U.S. Pharmaceutical Markets” with Joseph P. Newhouse, Patricia M. Danzon and Sean N. Nicholson, eds., Chapter 8 in The Oxford Handbook on the Economics of the Biopharmaceutical Industry, New York: Oxford University Press, pp. 201-265, 2012.

“The Segmentation of Therapeutic Populations in Oncology” with Mark R. Trusheim, Health Management, Policy and Innovation, 1(1):19-34, October 2012.

“The Segmentation of Therapeutic Populations in Oncology” with Mark R. Trusheim, Health Management, Policy and Innovation, 1(1):19-34, October 2012.

“The Unbundling of Advertising Agency Services: An Economic Analysis” with Mohammad Arzaghi, James C. Davis and Alvin J. Silk, Review E.R. Berndt, C.V - page 30 of Marketing Science, 10 (2012), Article 4. DOI:10.1515/1546-5616.1164. (2012)

“A Primer on the Economics of Prescription Pharmaceutical Pricing in Health Insurance Markets” with Thomas G. McGuire and Joseph P. Newhouse, Forum for Health Economics & Policy, 14(2), Article 10, November 2011.

“Advance Market Commitment for Pneumococcal Vaccines: Moving from Theory to Practice” with Tania Cernuschi, Eliane Furrer, Nina Schwalbe, Andrew Jones and Susan McAdams, Bulletin of the World Health Organization, posted online 14 October 2011, ID: BLT.11.08770

An Overview of Henry Grabowski's Scholarly Contributions (2011)

“Brand Loyalty, Generic Entry and Price Competition in Pharmaceuticals in the Quarter Century after the 1984 Waxman-Hatch Legislation” with Murray L. Aitken, International Journal of the Economics of Business, 18(2):177-201, July 2011.

”Diffusion of New Drugs in the Post-TRIPS Era”with Nathan Blalock and Iain M. Cockburn, International Journal of the Economics of Business, 18(2):203-24, July 2011.

“Economic Perspectives On The Advance Market Commitment For Pneumococcal Vaccines” with Christopher M. Snyder, Mark William Begor, Health Affairs, 30(8):1508-17, August 2011.

“Medicare Part D at Age Five: What Has Happened to Seniors' Prescription Drug Prices?” with Murray L. Aitken, Report by the IMS Institute for Healthcare Informatics, July 2011, 12 pp.

“Quality Adjustment for Healthcare Spending on Chronic Disease: Evidence from Diabetes Treatment, 1999-2009" American Economic Review, 101(3):206-211, May 2011. with Nilay D. Shah, Karen N. Eggleston, Steven A. Smith and Joseph P. Newhouse

“Quantifying Factors for the Success of Stratified Medicine” with Mark R Trusheim, Breon Burgess, Sean Xinghua Hu, Theresa Long, Steven D. Averbuch, Aiden A. Flynn, Alfons Lieftucht, Abhijit Mazumder, Judy Milloy, Peter Shaw, David Swank, Jian Wang, Federico Goodsaid and Michael C. Palmer, Nature Reviews: Drug Discovery, 10:817-33, November 2011.

“Bridging the Gap: Improving Clinical Development and the Regulatory Pathways for Health Products for Neglected Diseases” with Thomas J. Bollyky and Iain M. Cockburn, Clinical Trials, published online 25 November 2010, DOI: 10.1177/1740774510386390

“Characterizing Markets for Biopharmaceutical Innovations: Do Biologics Differ from Small Molecules?” with Mark R. Trusheim and Murray L. Aitken, Forum for Health Economics & Policy, Manuscript 1200, June 2010, 48 pp.

“Hedonic Price Indexes for Personal Computer Operating Systems and Productivity Suites” with Alan G. White, Jaison R. Abel and Cory W. Monroe, Annales d'Economie et de Statistique, Special Issue in Memory of Zvi Griliches, 79/80:787-807, 2005 (actually published June 2010).

“The Net Value of Health Care for Patients with Type 2 Diabetes, 1997 to 2005” with Karen N. Eggleston, Nilay D. Shah, Steven A. Smith, Amy E. Wagie, Arthur R. Williams, Jerome H. Grossman, Kirsten Hall Long, Ritesh Banerjee and Joseph P. Newhouse. Annals of Internal Medicine. 151(6):386-393, September 2009.

Energy Prices and Productivity Trends in the Canadian Manufacturing Sector, 1957-76 : Some Exploratory Results. Ottawa: Minister of Supply and Service Canada, 1981.

View complete list of publications (PDF) >>

 

Contact Information
Office: E62-518
Tel: (617) 253-2665
Fax: (617) 258-6786
Support Staff
Name: Tamar St. Julien
Tel: (617) 253-8318

General Expertise
Affordable Care Act (ACA); Applied economics; Applied microeconomics; Applied probability; Biopharmaceutical; Biotechnology; Cancer; Clinical trials; Data analytics; Drug models; Econometrics; Economics; Education; Game theory; Health management; Healthcare; Healthcare industry; HIV; Industrial organization; Industrial organization; Industrial partnerships; Institutional partnerships; Intellectual property; Intellectual property; Intellectual property law; Market research; Medicaid; Medical decision making; Medical devices; Medicare; Medicine; Microeconomics; Outsourcing; Pharmaceuticals; Pricing; Regulation and policy; Sampling; Statistics; Stochastic modeling